Publication Name	World Journal of Nephrology
Manuscript ID	11962
Country	United Kingdom

Received	2014-06-15 13:36
Peer-Review Started	2014-06-15 18:28
To Make the First Decision	2014-09-28 12:28
Return for Revision	2014-09-29 12:04
Revised	2014-10-07 02:55
Second Decision	2014-11-12 14:09
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-11-19 10:43
Articles in Press	2014-11-19 10:43
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-01-18 18:52
Publish the Manuscript Online	2015-02-07 09:38

ISSN	2220-6124 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Urology & Nephrology
Manuscript Type	Minireviews
Article Title	Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions
Manuscript Source	Invited Manuscript
All Author List	Ahad Qayyum, Elizabeth Ley Oei, Klara Paudel and Stanley L Fan
Funding Agency and Grant Number
Corresponding Author	Dr. Stanley L Fan, Department of Renal Medicine and Transplantation, The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London E1 1BB, United Kingdom. s.fan@qmul.ac.uk
Key Words	Individualized prescription; Biocompatibility; Peri­toneal dialysis; Glucose degradation products; Peritonitis; Ultrafiltration failure; Residual renal function
Core Tip	There is increasing evidence of benefit for using biocompatible and non-glucose based peritoneal dialysis (PD) fluids. However, cost remains an impe-diment and perhaps there are selected groups of patients where the cost can be justified. We suggest that biocompatible solutions should be considered for patients with residual renal function and/or expected to remain on PD for a long period. They are particularly helpful for patients with drain-in pains. The targeting of diabetic patients for non-glucose solutions is intriguing given the recent IMPENDIA/EDEN study although vigilance is required to minimize unaware hypoglycemia. It remains to be seen if PD nephrologists are willing to take the same leap of faith that our hemodialysis (HD) colleagues took when they moved from Acetate-based HD solutions to Bicarbonate dialysate. It is possible that economies of scale will reduce the cost of the biocompatible solutions if we use them more frequently.
Publish Date	2015-02-07 09:38
Citation	Qayyum A, Oei EL, Paudel K, Fan SL. Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions. World J Nephrol 2015; 4(1): 92-97
URL	http://www.wjgnet.com/2220-6124/full/v4/i1/92.htm
DOI	http://dx.doi.org/10.5527/wjn.v4.i1.92

Full Article (PDF)	WJN-4-92.pdf
Full Article (Word)	WJN-4-92.doc
Manuscript File	11962-Review.docx
Answering Reviewers	11962-Answering reviewers.pdf
Copyright License Agreement	11962-Copyright assignment.pdf
Peer-review Report	11962-Peer review(s).pdf
Scientific Misconduct Check	11962-CrossCheck.jpg
Scientific Editor Work List	11962-Scientific editor work list.pdf